The Memo: EndoShunt Medical Giving Surgeons the Gift of Time So They Can Give Patients the Gift of Life

Under the direction of CEO Tyler Zanon, EndoShunt Medical is developing a minimally invasive endovascular shunting device designed to give trauma surgeons temporary, targeted control over abdominal blood flow while maintaining perfusion to the rest of the body. In the most severe hemorrhage cases, where every minute can shape both survival and long-term quality of life, EndoShunt is working to replace blunt tools with a more controlled approach. As Zanon put it, “EndoShunt gives trauma surgeons the gift of time, so they can give trauma patients the gift of life.”

Origin Story

For Zanon, the mission behind EndoShunt is closely tied to the realities of trauma care. Based in Chicago, he has spent roughly 15 years in healthcare product development, first in academia and then in industry. Living in a major city with high rates of traumatic injury, he has seen how urgent the problem remains.

“We haven’t seen actual innovation since World War II,” Zanon said.

He often explains the challenge with a burst pipe analogy. When water is leaking, the options are either to apply pressure from the outside or shut off flow entirely. “While that’s great in plumbing, it’s not great in healthcare,” he said. “And that’s unfortunately exactly how surgeons are empowered to deal with abdominal bleeding today.”

That gap helped bring together a team of engineers, trauma surgeons, and medical device leaders around a shared goal: giving surgeons more time to perform definitive repairs without sacrificing downstream blood flow.

The Current Landscape

Today, trauma surgeons managing severe abdominal bleeding are often forced to choose between invasive packing, cross-clamping, or balloon occlusion. Each comes with serious tradeoffs.

Packing requires opening the patient and racing to locate the source of the bleed, often under extreme time pressure. Cross-clamping and balloon occlusion can reduce hemorrhage, but they do so by cutting off downstream blood flow, introducing a different set of risks.

“While that may mitigate bleeding, it starves our tissues of oxygen, and as little as 30 minutes can lead to irreversible damage as serious as blood poisoning, amputation, or even organ failure,” Zanon said.

That risk is not theoretical. Zanon described a case involving a 22-year-old patient with severe abdominal bleeding who underwent a blood flow restriction intervention and ultimately required a leg amputation.

“It’s a real problem for a predominantly young adult population who then has to go on with hopefully 70 years of life, but 70 years of very negatively impacted quality of life,” he said.

The burden extends beyond individual outcomes. According to EndoShunt, abdominal hemorrhage contributes to hundreds of thousands of fatalities globally each year, alongside high complication rates and billions in healthcare costs.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-memo-endoshunt-medical-giving-surgeons-the-gift-of-time-so-they-can-give-patients-the-gift-of-life

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

Microbot Medical and the Endovascular Robotics Opportunity Taking Shape

In November, Microbot Medical reached a meaningful milestone in the evolution of endovascular robotics, announcing that Emory University Hospital in Atlanta has become the first hospital worldwide to use the company’s LIBERTY system for patient care. Microbot is currently operating under a limited commercial release following FDA clearance, with a broader market launch planned for April 2026 at the Society of Interventional Radiology conference. While still early, the move signals growing confidence that robotic assistance inside the vasculature is beginning to transition from concept to clinical reality. To understand why this matters, it helps to step back and examine the numbers behind the endovascular robotics market and how Microbot’s approach fits into a rapidly evolving competitive landscape. Defining the Endovascular Procedure Landscape Endovascular procedures encompass any intervention performed from within a blood vessel. In practical terms, this includes coronary, periphe...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more